We found that a delay in anti-VEGF induction of up to one month among treatment-naïve exudative AMD patients does not increase the treatment burden as it neither affects the treatment interval nor the number of injections at 1-year and 2-year endpoints. Here, VEGFA is linked to age-related macular degeneration.